Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting ...

Visit the Investors and Media section of Mirum's corporate website for webcast links and additional information. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases ...

Mirum Pharmaceuticals, Inc. today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

SH-PEG-Stearic acid（巯基-聚乙二醇-硬脂酸） SH-PEG-Palmitic acid（巯基-聚乙二醇-棕榈酸） SH-PEG-Linoleic acid（巯基-聚乙二醇-亚油酸） SH-PEG-Linolenic acid（巯基-聚乙二醇-亚麻酸） SH-PEG-Arachidonic acid（巯基-聚乙二醇-花生四烯酸） SH-PEG-Cholic ...